Gene-Editing Therapy Lowers Cholesterol in Landmark Heart Disease Trial

AI Insight

Researchers conducted a clinical trial using VERVE-102, an in vivo base editing therapy that permanently modifies the PCSK9 gene in the liver to lower LDL cholesterol levels. The gene-editing treatment demonstrated sustained reductions in both PCSK9 protein levels and LDL cholesterol in patients with heterozygous familial hypercholesterolemia and established cardiovascular disease. This represents the first human application of in vivo base editing technology for a cardiovascular condition.

Why it matters

This one-time gene-editing treatment could offer a permanent alternative to daily cholesterol medications for patients with inherited high cholesterol and heart disease risk. The approach may reduce the burden of lifelong medication adherence and potentially lower cardiovascular event rates in high-risk populations.